These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
750 related articles for article (PubMed ID: 26552607)
1. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells. Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607 [TBL] [Abstract][Full Text] [Related]
2. A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression. Karacosta LG; Foster BA; Azabdaftari G; Feliciano DM; Edelman AM J Biol Chem; 2012 Jul; 287(29):24832-43. PubMed ID: 22654108 [TBL] [Abstract][Full Text] [Related]
3. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer. McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747 [TBL] [Abstract][Full Text] [Related]
4. Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer. Shima T; Mizokami A; Miyagi T; Kawai K; Izumi K; Kumaki M; Ofude M; Zhang J; Keller ET; Namiki M Prostate; 2012 Dec; 72(16):1789-801. PubMed ID: 22549914 [TBL] [Abstract][Full Text] [Related]
5. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity. Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760 [TBL] [Abstract][Full Text] [Related]
6. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
7. Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors. Li N; Chen M; Truong S; Yan C; Buttyan R Prostate; 2014 Oct; 74(14):1400-10. PubMed ID: 25132524 [TBL] [Abstract][Full Text] [Related]
8. GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling. White MA; Tsouko E; Lin C; Rajapakshe K; Spencer JM; Wilkenfeld SR; Vakili SS; Pulliam TL; Awad D; Nikolos F; Katreddy RR; Kaipparettu BA; Sreekumar A; Zhang X; Cheung E; Coarfa C; Frigo DE Endocr Relat Cancer; 2018 Apr; 25(4):453-469. PubMed ID: 29431615 [TBL] [Abstract][Full Text] [Related]
9. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling. Lin C; Blessing AM; Pulliam TL; Shi Y; Wilkenfeld SR; Han JJ; Murray MM; Pham AH; Duong K; Brun SN; Shaw RJ; Ittmann MM; Frigo DE Oncogene; 2021 Mar; 40(9):1690-1705. PubMed ID: 33531625 [TBL] [Abstract][Full Text] [Related]
11. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960 [TBL] [Abstract][Full Text] [Related]
12. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer. Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396 [TBL] [Abstract][Full Text] [Related]
13. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells. Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308 [TBL] [Abstract][Full Text] [Related]
15. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells. Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225 [TBL] [Abstract][Full Text] [Related]
16. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription. Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975 [TBL] [Abstract][Full Text] [Related]
17. A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer. Capaia M; Granata I; Guarracino M; Petretto A; Inglese E; Cattrini C; Ferrari N; Boccardo F; Barboro P Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966326 [TBL] [Abstract][Full Text] [Related]
18. [Regulatory effect of Skp2 on the expression and transactivation of the androgen receptor in the progression of castration-resistant prostate cancer]. Song YT; Wu KJ; Wang XY; Na YG; Yin CM Zhonghua Nan Ke Xue; 2016 Feb; 22(2):122-7. PubMed ID: 26939395 [TBL] [Abstract][Full Text] [Related]
19. Androgen receptor transcriptional activity is required for heregulin-1β-mediated nuclear localization of the HER3/ErbB3 receptor tyrosine kinase. Jathal MK; Siddiqui S; Vasilatis DM; Durbin Johnson BP; Drake C; Mooso BA; D'Abronzo LS; Batra N; Mudryj M; Ghosh PM J Biol Chem; 2023 Aug; 299(8):104973. PubMed ID: 37380074 [TBL] [Abstract][Full Text] [Related]
20. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures. Chattopadhyay I; Wang J; Qin M; Gao L; Holtz R; Vessella RL; Leach RW; Gelman IH Oncotarget; 2017 Feb; 8(6):10324-10347. PubMed ID: 28055971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]